• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坏死在少突胶质细胞瘤分级中的意义:一项对新诊断的高级别胶质瘤的临床病理和遗传学研究

Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

作者信息

Miller C Ryan, Dunham Christopher P, Scheithauer Bernd W, Perry Arie

机构信息

Division of Neuropathology, Washington University School of Medicine, St Louis, MO 63110, USA.

出版信息

J Clin Oncol. 2006 Dec 1;24(34):5419-26. doi: 10.1200/JCO.2006.08.1497.

DOI:10.1200/JCO.2006.08.1497
PMID:17135643
Abstract

PURPOSE

High-grade gliomas (HGGs; WHO grades 3-4) are highly diverse, with survival times ranging from months to years. WHO 2000 grading criteria for high-grade oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO)] remain subjective, and the existence of grade 4 variants is controversial.

PATIENTS AND METHODS

Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery type, year of diagnosis, endothelial proliferation, necrosis, oligodendroglial histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).

RESULTS

Necrosis was a statistically significant predictor of poor OS on univariate and multivariate analyses in AOA but not in AO. Median OS for patients with necrotic AOA (22.8 months) was significantly worse than for patients with non-necrotic AOA (86.9 months; P < .0001) but was better than conventional glioblastomas (9.8 months; P < .0001). In addition to patient age, the following were significant independent prognostic factors (P .001): grade and surgery type for the entire HGG cohort; modified grade for AOA (3 v 4); and modified grade, 1p/19q codeletion status, and oligodendroglial histology for the 586 HGGs analyzed by FISH.

CONCLUSION

Stratification of AOA, but not of pure AO, into grades 3 and 4 on the basis of necrosis is prognostically justified and is more powerful than the current approach. Both routine histology and genetic testing provide independent, prognostically useful information.

摘要

目的

高级别胶质瘤(HGG;世界卫生组织3 - 4级)具有高度多样性,生存时间从数月到数年不等。世界卫生组织2000年关于高级别少突胶质细胞瘤[间变性少突星形细胞瘤(AOA)和间变性少突胶质细胞瘤(AO)]的分级标准仍然主观,且4级变体的存在存在争议。

患者与方法

对1990年至2005年间新诊断的1093例成人脑HGG患者的总生存期(OS)进行单因素和多因素模型分析,以确定以下因素的显著性:患者年龄、手术类型、诊断年份、内皮细胞增殖、坏死、少突胶质细胞组织学、治疗中心以及通过荧光原位杂交(FISH)检测的1号染色体短臂(1p)、19号染色体长臂(19q)、7号染色体短臂(EGFR)和10号染色体长臂(PTEN)异常情况。

结果

在单因素和多因素分析中,坏死是AOA患者OS较差的统计学显著预测因素,但在AO患者中并非如此。坏死性AOA患者的中位OS(22.8个月)显著差于非坏死性AOA患者(86.9个月;P <.0001),但优于传统胶质母细胞瘤(9.8个月;P <.0001)。除患者年龄外,以下因素为显著的独立预后因素(P <.001):整个HGG队列的分级和手术类型;AOA的改良分级(3级对4级);以及通过FISH分析的586例HGG的改良分级、1p/19q共缺失状态和少突胶质细胞组织学。

结论

基于坏死将AOA(而非纯AO)分为3级和4级在预后方面是合理的,且比当前方法更有效。常规组织学和基因检测均提供独立的、对预后有用的信息。

相似文献

1
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.坏死在少突胶质细胞瘤分级中的意义:一项对新诊断的高级别胶质瘤的临床病理和遗传学研究
J Clin Oncol. 2006 Dec 1;24(34):5419-26. doi: 10.1200/JCO.2006.08.1497.
2
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.组织学和1p/19q状态在间变性少突胶质细胞瘤中的预后影响
Cancer. 2005 Oct 1;104(7):1468-77. doi: 10.1002/cncr.21338.
3
[Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].[分子遗传因素对少突胶质细胞瘤患者预后的影响]
Zh Vopr Neirokhir Im N N Burdenko. 2009 Jan-Mar(1):17-23; discussion 23-4.
4
Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.少突胶质细胞瘤患者基因改变与长期临床结局的相关性,以及1号染色体短臂上一个一致缺失区域的鉴定。
Cancer. 2003 May 1;97(9):2254-61. doi: 10.1002/cncr.11322.
5
Prognostic stratification of patients with anaplastic gliomas according to genetic profile.根据基因特征对间变性胶质瘤患者进行预后分层。
Cancer. 2006 Oct 15;107(8):1891-7. doi: 10.1002/cncr.22211.
6
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.在一项前瞻性随机研究中对间变性少突胶质细胞瘤进行的分子分析:来自 EORTC 研究 26951 的报告。
Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011.
7
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.欧洲癌症研究与治疗组织26951试验中间变性少突胶质细胞瘤的专家组审查:诊断共识评估、1p/19q缺失的影响及与预后的相关性
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51. doi: 10.1097/01.jnen.0000263869.84188.72.
8
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?少突胶质细胞瘤中1p/19q联合缺失:预测性还是预后性生物标志物?
Clin Cancer Res. 2007 Dec 1;13(23):6933-7. doi: 10.1158/1078-0432.CCR-07-0573.
9
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.小细胞星形细胞瘤:一种侵袭性变体,在临床病理和基因方面与间变性少突胶质细胞瘤不同。
Cancer. 2004 Nov 15;101(10):2318-26. doi: 10.1002/cncr.20625.
10
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.局部诊断为间变性少突胶质细胞瘤或少突星形细胞瘤患者的新临床、病理和分子预后模型和计算器。欧洲癌症研究与治疗组织脑肿瘤组研究 26951 的预后因素分析。
Eur J Cancer. 2013 Nov;49(16):3477-85. doi: 10.1016/j.ejca.2013.06.039. Epub 2013 Jul 26.

引用本文的文献

1
1p and/or 19q polysomy is an adverse prognostic factor in oligodendrogliomas, and easy to detect by automated FISH.1p和/或19q多体性是少突胶质细胞瘤的不良预后因素,且易于通过自动化荧光原位杂交(FISH)检测到。
PLoS One. 2025 May 2;20(5):e0322809. doi: 10.1371/journal.pone.0322809. eCollection 2025.
2
The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis.术前肿瘤内出血的胶质瘤的分子特征和预后:一项回顾性队列分析。
BMC Neurol. 2024 Jun 14;24(1):202. doi: 10.1186/s12883-024-03703-2.
3
Expression of intra-tumoral necrosis-associated cytokine pattern correlated with prognosis and immune status in glioma.
肿瘤内坏死相关细胞因子模式的表达与胶质瘤的预后和免疫状态相关。
Front Mol Neurosci. 2023 Jul 3;16:1117237. doi: 10.3389/fnmol.2023.1117237. eCollection 2023.
4
Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations.通过分子动力学模拟探究双突变T790M/L858R对表皮生长因子受体构象及耐药机制的影响
RSC Adv. 2018 Nov 29;8(70):39797-39810. doi: 10.1039/c8ra06844e. eCollection 2018 Nov 28.
5
Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.预测少突胶质细胞瘤分级的影像学解读挑战:神经肿瘤学分会的报告。
CNS Oncol. 2022 Mar 1;11(1):CNS83. doi: 10.2217/cns-2021-0005. Epub 2022 Feb 10.
6
Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma.原发性胶质母细胞瘤患者预后中颞肌厚度测量在颅脑磁共振成像上的预测价值
Front Neurol. 2020 Nov 12;11:523292. doi: 10.3389/fneur.2020.523292. eCollection 2020.
7
Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity.对整块切除的少突胶质细胞瘤的 PET、MRI 和组织学进行分区分析显示肿瘤内存在异质性。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):569-579. doi: 10.1007/s00259-018-4107-z. Epub 2018 Aug 14.
8
Prognostic factors and outcomes in anaplastic gliomas: An institutional experience.间变性胶质瘤的预后因素与结局:一项机构经验
South Asian J Cancer. 2018 Jan-Mar;7(1):1-4. doi: 10.4103/sajc.sajc_55_17.
9
Recent developments in predictive biomarkers of pediatric glioma.小儿胶质瘤预测生物标志物的最新进展。
Oncol Lett. 2017 Jul;14(1):497-500. doi: 10.3892/ol.2017.6243. Epub 2017 May 24.
10
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.《2016年世界卫生组织中枢神经系统肿瘤分类:修订要点》
Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8.